Current markers include plasma levels of chromogranin A, tumor metastases and Ki67 staining to determine the tumor proliferation rate ... to predict survival in patients with neuroendocrine ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.